Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Evidence for SBF1 involvement in Charcot-Marie-Tooth disease type 4B3 (CMT4B3) remains limited. A novel heterozygous missense variant, c.1398C>A (p.His466Gln), was identified in a mother–daughter pair with early-onset distal limb amyotrophy, normal nerve conduction velocities, and autosomal dominant transmission (PMID:39664754). Separately, three unrelated CMT4B3 patients harboring homozygous SBF1 mutations have been used to generate induced pluripotent stem cell lines, providing a resource to study MTMR5 dysfunction but not yet yielding phenotypic rescue or in vivo confirmation (PMID:39461113). Additionally, targeted sequencing of 612 hereditary neuropathy cases detected rare SBF1 loss-of-function alleles among diverse CMT and related neuropathies, suggesting recurring mutation across neuropathic phenotypes (PMID:28902413). Biallelic truncating variants co-segregate in two families with autosomal recessive axonal neuropathy and additional cranial involvement, supporting a wider phenotypic spectrum but lacking large pedigrees or functional validation in vivo (PMID:28005197). The heterogeneity of inheritance (dominant vs recessive), small family sizes, and absence of robust animal or rescue studies limit the current clinical validity of SBF1–CMT4B3. Key take-home: while rare SBF1 variants segregate with neuropathy in few families and iPSC models exist, additional large pedigrees and functional rescue experiments are needed before routine diagnostic use.
Gene–Disease AssociationLimitedFive probands in four families (two dominant, three recessive) with segregation in one pedigree and preliminary iPSC models Genetic EvidenceLimitedTwo probands segregating a novel missense AD variant and three AR homozygotes with co-segregation in small families Functional EvidenceLimitediPSC lines from three homozygous patients demonstrate MTMR5 dysfunction without in vivo or rescue studies |